A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT Save

Date Added
February 28th, 2017
PRO Number
Pro00062003
Researcher
James Thomas

Silhouette
Keywords
Cardiovascular, Cholesterol
Summary

Research study looking for participants with, or at high risk for, cardiovascular disease (CVD). This study is being carried out to see if a new investigational drug called bempedoic acid provides cardiovascular benefits and decreases the risks of future cardiac events when taken by patients who are not able to take a type of medication called statins. The study may require up to 15 visits to the clinic over a period of five years.

Institution
MUSC
Recruitment Contact
Della MacNicholas
843-876-5012
macnichd@musc.edu

CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia Save

Date Added
January 2nd, 2017
PRO Number
Pro00059316
Researcher
Pamela Morris

Silhouette
Keywords
Cardiovascular, Cholesterol
Summary

The CASCADE FH Registry is a national, multi?center initiative that will track the therapy, clinical outcomes, and patient?reported outcomes over time. The Registry represents collaboration between The FH Foundation, lipid specialists, cardiologists, primary care providers, quality improvement personnel, and patients, all aiming to increase FH awareness, promote optimal disease management, and improve FH outcomes. The Duke Clinical Research Institute will help operationalize the clinical portal of the CASCADE FH Registry. The Registry will use a hybrid enrollment design to maximize outreach and ensure that all interested FH patients have the option to participate. In accordance with these goals, participants will be identified using a variety of mechanisms, including screening by providers and online screening tools available to the general public. MUSC will only follow the clinical, prospective data collection method outlined in the protocol for this study. Cross?validation of clinical data with patient?entered data will optimize quality and promote statistical validity.

Institution
MUSC
Recruitment Contact
Ariane Shokri
843792-1274
shokria@musc.edu

AEGR-733-025; LOWER: Lomitapide Observational Worldwide Evaluation Registry Save

Date Added
August 20th, 2015
PRO Number
Pro00043207
Researcher
Vince Vismara
Keywords
Cholesterol
Summary

This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide. The purpose is to evaluate the occurrence of adverse events of special interest, long term effectiveness of Lomitapide, and to evaluate whether prescribers of Lomitapide are following screening and monitoring recommendations as specified in product labeling.

Institution
Palmetto
Recruitment Contact
Monica Lynn
803-434-4338
monica.lynn@palmettohealth.org

Randomized Trial to Prevent Vascular Events in HIV ? REPRIEVE (A5332) Save

Date Added
June 16th, 2015
PRO Number
Pro00042920
Researcher
Allison Eckard

Silhouette
Keywords
Cardiovascular, Cholesterol, Disease Prevention, Drug Studies, Heart, HIV / AIDS, Infectious Diseases
Summary

Pitavastatin lowers high cholesterol and triglyceride levels in the blood. The primary purpose of this study is to determine the effects of pitavastatin on lowering the traditional risk factors for cardiological events in patients who have HIV.

Institution
MUSC
Recruitment Contact
Stephanie Warth
843-792-5491
warth@musc.edu

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia Save

Date Added
April 22nd, 2014
PRO Number
Pro00033939
Researcher
James Thomas

Silhouette
Keywords
Cardiovascular, Cholesterol, Diabetes, Heart, Stroke
Summary

Research study looking for participants with high triglycerides and either cardiovascular disease or risk factors for cardiovascular disease (e.g.history of heart attack, stroke, stent placement or diabetes type 1 or 2.) This study is being carried out to see if a new investigational drug called Epanova® when added to current treatment for high cholesterol, stroke, and death from heart disease, when compared with placebo (inactive pill having no effect). Medications, all study visits, blood work and study procedures are free of charge.

Institution
MUSC
Recruitment Contact
Della MacNicholas
843-876-5012
macnichd@musc.edu

Change_preferences

-- OR --

Create_login